Bicocca Open Archive

Logo unimib boa

Pronzato, P., Mustacchi, G., Riccardi, F., Turletti, A., Michelotti, A., Natoli, C., et al. (2017). Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study. Intervento presentato a: 19th National Congress of Medical Oncology, Rome, Italy [10.1093/annonc/mdx424.024].

Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

Cazzaniga M.
2017
abstract + poster
breast cancer
English
19th National Congress of Medical Oncology
2017
2017
28
Suppl 6
Meeting Abstract: C25
none
Pronzato, P., Mustacchi, G., Riccardi, F., Turletti, A., Michelotti, A., Natoli, C., et al. (2017). Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study. Intervento presentato a: 19th National Congress of Medical Oncology, Rome, Italy [10.1093/annonc/mdx424.024].
02 - Intervento a convegno
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/282005
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
Social impact